Celgene Corporation (CELG) - FREE Research Report

Karsen Perry A who is see remarks at Celgene Corporation sold 2,408 shares at $159.05 on March 5, 2014. Following this transaction, the see remarks owned 25,960 shares meaning that the stake was reduced by 8.49% with the 2,408-share transaction.

The shares most recently traded at $160.89, up $1.84, or 1.14% since the insider transaction. Historical insider transactions for Celgene Corporation go as follows:

  • 24-Week # shares bought: 1,000

The average volume for Celgene Corporation has been 3.1 million shares per day over the past 30 days. Celgene Corporation has a market cap of $65.7 billion and is part of the health care sector and drugs industry. Shares are down 4.22% year-to-date as of the close of trading on Wednesday.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company has a P/E ratio of 48.0. Currently there are 24 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CELG - FREE

TheStreet Quant Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Cramer: These Sectors Look Bullish (Part III)

Cramer: There Are Powerful Themes in Several Bull Markets

Stanley Black & Decker, Quest Diagnostics and 2 More Could Rocket Higher This Spring -- Here's Why

MasterCard, Intuitive Surgical and 2 More Could Rocket Higher This Spring--Here's Why …

Market Recon: If You Are Scared, Don't Show It